Protara Therapeutics (TARA) Other Working Capital Changes (2013 - 2026)
Protara Therapeutics (TARA) posted quarterly Other Working Capital Changes of -$302000.0 for Q1 2026, down 17.97% year-over-year from -$368152.4 in Q1 2025, and down 1.68% quarter-over-quarter from -$297000.0 in Q4 2025.
Powered by 
Analysis
Protara Therapeutics (TARA) Other Working Capital Changes (2013 - 2026) Analysis & Trends
Protara Therapeutics (TARA) has reported Other Working Capital Changes for 3 consecutive years, with -$302000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Working Capital Changes fell 17.97% year-over-year to -$302000.0; the TTM figure through Mar 2026 stood at -$1.2 million (down 17.0% YoY), while the FY2025 annual figure was -$1.1 million, down 14.23% from the prior year.
- Other Working Capital Changes retreated to -$302000.0 in Q1 2026 per TARA's latest filing, from -$297000.0 in the prior quarter.
- Across five years, Other Working Capital Changes topped out at $6.1 million in Q1 2023 and bottomed at -$4.1 million in Q2 2023.
- Historically, Other Working Capital Changes has averaged $237411.8 across 5 years, with a median of -$60000.0 in 2025.
- Annual changes were most pronounced in 2025 — Other Working Capital Changes dropped 6.67% — and 2026, when it dropped 17.97%.
- Protara Therapeutics' Other Working Capital Changes stood at -$253000.0 in 2024, then decreased by 17.39% to -$297000.0 in 2025, then fell by 1.68% to -$302000.0 in 2026.
- Business Quant data shows TARA's Other Working Capital Changes at -$302000.0 in Q1 2026, -$297000.0 in Q4 2025, and -$292000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Protara Therapeutics | 241.28 Mn | 241.28 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -402,000.00 |
| Jun 30, 2026 | -402,000.00 |
| Mar 31, 2026 | -302,000.00 |
| Mar 31, 2026 | -302,000.00 |
| Dec 31, 2025 | 976,000.00 |
| Dec 31, 2025 | 976,000.00 |
| Sep 30, 2025 | 99,000.00 |
| Sep 30, 2025 | 99,000.00 |
| Jun 30, 2025 | 706,000.00 |
| Jun 30, 2025 | 706,000.00 |
| Mar 31, 2025 | 306,000.00 |
| Mar 31, 2025 | 306,000.00 |
| Dec 31, 2024 | -531,000.00 |
| Dec 31, 2024 | -531,000.00 |
| Sep 30, 2024 | -239,000.00 |
| Sep 30, 2024 | -239,000.00 |
| Jun 30, 2024 | -57,000.00 |
| Jun 30, 2024 | -57,000.00 |
| Mar 31, 2024 | -435,000.00 |
| Mar 31, 2024 | -435,000.00 |